Pivotal Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

/PRNewswire/ Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA.

San antonioUnited statesNew zealandDan schneiderHexvix cysviewPrnewswire photocureDavid moskowitzSanjay dasErik dahlCysview hexvixSteven williamsBladder cancer companyCorporate communications norwayAmerican cancer societyOslo stock exchangeAffairs va healthcare

Photocure: Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure: Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSan antonioNew zealandSanjay dasErik dahlDavid moskowitzExperte carsten storkDan schneiderSteven williamsZwei rohstoff chancenHexvix cysviewPrnewswire photocureCysview hexvixAmerican cancer societyCorporate communications norwayOslo stock exchange

Ablative Solutions TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation

/PRNewswire/ Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal.

United statesKate rumrillDavid kandzariAblative solutionsAmerican college of cardiologyScientific congressPiedmont heart institutePrnewswire ablative solutions incAblative solutions incLate breaking clinical trialPrimary endpointUncontrolled hypertensionTreatment armPivotal trialPeregrine systemAmerican college

Protembis GmbH: Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Protembis GmbH: Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStephan haussig herzzentrumConrad rasmus karlDennis riedlProtembis gmbRaj makkar cedarsRoxana mehran mountLos angelesProtembis gmbhStudy executive committeeGlobal coBoston scientificSuperiority trialDemonstrate effectiveness againstCurrently approved sentinelDevice exemption

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

NEW YORK & AACHEN, Germany, April 02, 2024 Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection devic

United statesRoxana mehran mountConrad rasmus karlRaj makkar cedarsLos angelesProtembis gmbhStephan haussig herzzentrumProtembis gmbGlobal coStudy executive committeeBoston scientificSuperiority trialDemonstrate effectiveness againstCurrently approved sentinelDevice exemptionPivotal trial